Merck is trading at $155.28, up +3.06% (about 3.1%), with no clear new catalyst; recent bullish analyst target increases and positive oncology-trial momentum may be supporting sentiment.

  • Broader indexes are higher, but not strongly enough to establish a market-wide cause
  • August 25, 2026 coverage highlighted a federal judge’s unfavorable dismissal of Merck’s Medicare negotiation challenge
  • The legal outcome does not explain the gain, leaving conflicting company-specific signals